Rafael Holdings, Inc. revenue
Rafael Holdings, Inc.'s revenue was $874,000 in fiscal 2026, down 4.7% on the year before. Since fiscal 2016 ($5.6m) it has grown at a compound -16.9% a year.
Revenue history
| Fiscal year | 2016Jul 2016 | 2017Jul 2017 | 2018Jul 2018 | 2019Jul 2019 | 2020Jul 2020 | 2021Jul 2021 | 2022Jul 2022 | 2023Jul 2023 | 2024Jul 2024 | 2025Jul 2025 | 2026Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,589 | 5,618 | 4,371 | 4,931 | 4,910 | 802 | 410 | 279 | 637 | 917 | 874 |
| Growth on the year before | — | +0.5% | −22.2% | +12.8% | −0.4% | −83.7% | −48.9% | −32.0% | +128.3% | +44.0% | −4.7% |
| Gross profit | — | — | — | — | — | −2,367 | −3,089 | — | 483 | — | — |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Product Revenue | $519,000 | ▲ 0.8% |
| Health Care | $519,000 | ▲ 1630.0% |
| Rental Third Party | $236,000 | ▲ 19.8% |
| Rental Related Party | $119,000 | ▲ 6.2% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Rafael Holdings, Inc.'s 10-K filed October 29, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Rafael Holdings, Inc. | $874,000 | -4.7% | 46.3% |
| Medicinova Inc | $920,481 | 875.7% | — |
| Shattuck Labs, Inc. | $1.0m | -66.6% | 5.2% |
| Longeveron Inc. | $1.2m | -42.7% | 10.4% |
| Dare Bioscience, Inc. | $1.4m | 4366.5% | — |
| Cartesian Therapeutics, Inc. | $1.5m | 44.0% | -68.8% |
Compare with peers
- Medicinova Inc revenue
- Shattuck Labs, Inc. revenue
- Longeveron Inc. revenue
- Dare Bioscience, Inc. revenue
- Cartesian Therapeutics, Inc. revenue
Head to head: MNOV vs RFLRFL vs STTKLGVN vs RFL
More: Biotechnology stocks compared, Health Care sector, rankings of US companies